Beth Phillips

[Beth Phillips @phillibeth]

@JudithTrotman1 @ALLGtrials @SFBarringtonKCL @PWMJohnson @CraigMoskMD @graham74GC Fantastic to hear!

[Beth Phillips @phillibeth]

@AdeleKFielding @rosebud2605 @CavetJim @DrAmitPatel @mikewdennis @dwiseman78 Good news (for us)! Looking forward to seeing you again Rosie

[Beth Phillips @phillibeth]

@BritSocHaem Congratulations @JBomsztyk

[André Marc @MarcAndre64]

ABVD vs BEACOPP in advanced Hodgkin. New data for an old controversy! Our paper is just published in Cancer Medicine
https://t.co/25fWi0vhdz

[Beth Phillips @phillibeth]

@graham74GC It strikes me that these results aren’t vastly different from H10 unfavourable. This is the group that has the least benefit from RT irrespective of chemo regimen. I’m not sure this should convince us to use more eBEACOPP if HD14 didn’t.

[Graham Collins @graham74GC]

Phillips et al - @NCRI_partners INCA trial
• randomised trial in anthracycline unfit DLBCL 1L (1st ever?)
• RGCVP v R-CVP+inotuzumab
• 129 pts, med age 79
• NRM 25%! - high risk
• no benefit for RCVP-IO (although prespecified IPI3-5 subgroup did show benefit)
#lymsm #EHA25

[Adam Mead @AdamMead_Oxford]

Huge dataset. Kudos to @bengoldacre and team. Haem malignancy pts are at particular risk. Immunesuppression? Aberrant inflammation? Treatment? These diseases are highly heterogeneous = urgent need for more granularity & implementation of evidence-based management in COVID-19 era.

[Toby Eyre @tobyeyre82]

Highly effective therapy in #Burkitts #lymphoma. Nice work @andrewmac2018
@phillibeth #lymsm

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial https://t.co/52PoNllqiu

[Beth Phillips @phillibeth]

For the first time in my life, I feel that my vote in a general election might actually make a difference. Makes you realise just how powerful proportional representation could be. C’mon #Putney #GE2019 #VoteNHS

[David Steensma, MD @DavidSteensma]

@chadinabhan @tobyeyre82 @graham74GC This is the classic 1983 (!) @jco_asco paper by Anderson et al on the inherent flaws of responder vs nonresponder analyses. I’ve cited it as a manuscript reviewer so many times that I finally made a macro so I could stop retyping the same dang thing again and again.@VPrasadMDMPH

[Beth Phillips @phillibeth]

GHSG HD16 study: PET-positive patients after 2ABVD have worse outcomes in early-stage HL. But how is Deauville 4 defined and where are the D5s? RAPID data show that not all ‘positive’ PETs are equal

[Beth Phillips @phillibeth]

A game-changer for frontline CLL? PFS and OS advantage for IR over FCR #ASH18 https://t.co/Uwh3eepNnZ